The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Frederick Wolfe

National Data Bank for Rheumatic Diseases

1035 N. Emporia

Suite 288

Wichita

USA

[email]@arthritis-research.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • National Data Bank for Rheumatic Diseases, 1035 N. Emporia, Suite 288, Wichita, USA. 2012
  • National Data Bank for Rheumatic Diseases and University of Kansas School of Medicine, Wichita, KS 67214, USA. 2000 - 2011
  • University of Kansas School of Medicine, Kansas, USA. 2009

References

  1. Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice. Masri, K.R., Shaver, T.S., Shahouri, S.H., Wang, S., Anderson, J.D., Busch, R.E., Michaud, K., Mikuls, T.R., Caplan, L., Wolfe, F. J. Rheumatol. (2012) [Pubmed]
  2. Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Wolfe, F., Hassett, A.L., Walitt, B., Michaud, K. Arthritis. Care. Res. (Hoboken) (2011) [Pubmed]
  3. The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Wolfe, F., Häuser, W., Hassett, A.L., Katz, R.S., Walitt, B.T. Pain (2011) [Pubmed]
  4. Do We Need Core Sets of Fibromyalgia Domains? The Assessment of Fibromyalgia (and Other Rheumatic Disorders) in Clinical Practice. Wolfe, F., Hassett, A.L., Katz, R.S., Michaud, K., Walitt, B. J. Rheumatol. (2011) [Pubmed]
  5. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Wolfe, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L., Häuser, W., Katz, R.S., Mease, P., Russell, A.S., Russell, I.J., Winfield, J.B. J. Rheumatol. (2011) [Pubmed]
  6. The longitudinal outcome of fibromyalgia: a study of 1555 patients. Walitt, B., Fitzcharles, M.A., Hassett, A.L., Katz, R.S., Häuser, W., Wolfe, F. J. Rheumatol. (2011) [Pubmed]
  7. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Wolfe, F., Michaud, K. Arthritis Res. Ther. (2010) [Pubmed]
  8. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. Wolfe, F., Michaud, K., Wallenstein, G. J. Rheumatol. (2010) [Pubmed]
  9. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. Wolfe, F., Michaud, K., Li, T., Katz, R.S. J. Rheumatol. (2010) [Pubmed]
  10. The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness. Wolfe, F., Michaud, K. J. Rheumatol. (2010) [Pubmed]
  11. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Wolfe, F., Marmor, M.F. Arthritis. Care. Res. (Hoboken) (2010) [Pubmed]
  12. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Wolfe, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L., Katz, R.S., Mease, P., Russell, A.S., Russell, I.J., Winfield, J.B., Yunus, M.B. Arthritis. Care. Res. (Hoboken) (2010) [Pubmed]
  13. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. Wolfe, F., Michaud, K., Li, T., Katz, R.S. J. Rheumatol. (2010) [Pubmed]
  14. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. Wolfe, F., Petri, M., Alarcón, G.S., Goldman, J., Chakravarty, E.F., Katz, R.S., Karlson, E.W. J. Rheumatol. (2009) [Pubmed]
  15. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Wolfe, F., Michaud, K. Arthritis Rheum. (2009) [Pubmed]
  16. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. Wolfe, F., Michaud, K. J. Rheumatol. (2009) [Pubmed]
  17. Remission in rheumatoid arthritis: physician and patient perspectives. Wolfe, F., Boers, M., Felson, D., Michaud, K., Wells, G.A. J. Rheumatol. (2009) [Pubmed]
  18. Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. Wolfe, F., Michaud, K. J. Rheumatol. (2009) [Pubmed]
  19. Fibromyalgia wars. Wolfe, F. J. Rheumatol. (2009) [Pubmed]
  20. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Wolfe, F., Michaud, K. Arthritis Rheum. (2008) [Pubmed]
  21. Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. Wolfe, F., Michaud, K. J. Rheumatol. (2008) [Pubmed]
  22. The challenges of determining RA disease activity and remission in clinical practice. Wolfe, F., Michaud, K. Nature Clinical Practice. Rheumatology (2008) [Pubmed]
  23. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. Wolfe, F., Allaire, S., Michaud, K. J. Rheumatol. (2007) [Pubmed]
  24. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Wolfe, F., Rasker, J.J., Boers, M., Wells, G.A., Michaud, K. Arthritis Rheum. (2007) [Pubmed]
  25. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Wolfe, F., Caplan, L., Michaud, K. Scand. J. Rheumatol. (2007) [Pubmed]
  26. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Wolfe, F., Michaud, K. Arthritis Rheum. (2007) [Pubmed]
  27. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. Wolfe, F., Michaud, K. J. Rheumatol. (2007) [Pubmed]
  28. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Wolfe, F., Michaud, K. Arthritis Rheum. (2007) [Pubmed]
  29. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Wolfe, F., Michaud, K. Arthritis Rheum. (2007) [Pubmed]
  30. The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. Wolfe, F., Rasker, J.J. J. Rheumatol. (2006) [Pubmed]
  31. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Wolfe, F., Michaud, K., Chakravarty, E.F. Rheumatology. (Oxford) (2006) [Pubmed]
  32. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Wolfe, F., Caplan, L., Michaud, K. Arthritis Rheum. (2006) [Pubmed]
  33. Anemia and renal function in patients with rheumatoid arthritis. Wolfe, F., Michaud, K. J. Rheumatol. (2006) [Pubmed]
  34. Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases?. Wolfe, F., Michaud, K., Simon, T. J. Rheumatol. (2006) [Pubmed]
  35. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. Wolfe, F., Michaud, K., Li, T. J. Rheumatol. (2006) [Pubmed]
  36. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. Wolfe, F., Michaud, K., Strand, V. J. Rheumatol. (2005) [Pubmed]
  37. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. Wolfe, F., Michaud, K., Pincus, T. J. Rheumatol. (2005) [Pubmed]
  38. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. Wolfe, F., Michaud, K., Choi, H.K., Williams, R. J. Rheumatol. (2005) [Pubmed]
  39. Why the HAQ-II can be an effective substitute for the HAQ. Wolfe, F. Clin. Exp. Rheumatol. (2005) [Pubmed]
  40. A brief introduction to the National Data Bank for Rheumatic Diseases. Wolfe, F., Michaud, K. Clin. Exp. Rheumatol. (2005) [Pubmed]
  41. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Wolfe, F., Michaud, K. Rheumatology. (Oxford) (2005) [Pubmed]
  42. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Wolfe, F., Michaud, K., Pincus, T., Furst, D., Keystone, E. Arthritis Rheum. (2005) [Pubmed]
  43. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). Wolfe, F., Michaud, K., Pincus, T. J. Rheumatol. (2005) [Pubmed]
  44. Jaw pain: its prevalence and meaning in patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia. Wolfe, F., Katz, R.S., Michaud, K. J. Rheumatol. (2005) [Pubmed]
  45. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. Wolfe, F., Michaud, K., Burke, T.A., Zhao, S.Z. J. Rheumatol. (2004) [Pubmed]
  46. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Wolfe, F., Michaud, K., Anderson, J., Urbansky, K. Arthritis Rheum. (2004) [Pubmed]
  47. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Wolfe, F., Michaud, K. Am. J. Med. (2004) [Pubmed]
  48. A short history of data banking in the United States from 1974 to 2003. Wolfe, F. J. Rheumatol. Suppl (2004) [Pubmed]
  49. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. Wolfe, F., Michaud, K. J. Rheumatol. (2004) [Pubmed]
  50. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. Wolfe, F., Zhao, S., Pettitt, D. J. Rheumatol. (2004) [Pubmed]
  51. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Wolfe, F., Michaud, K. Arthritis Rheum. (2004) [Pubmed]
  52. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. Wolfe, F. J. Rheumatol. (2004) [Pubmed]
  53. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Wolfe, F., Michaud, K., Pincus, T. Arthritis Rheum. (2004) [Pubmed]
  54. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Wolfe, F., Michaud, K., Dewitt, E.M. Ann. Rheum. Dis. (2004) [Pubmed]
  55. Data collection, maintenance, and analysis for rheumatic disease research. Wolfe, F., Michaud, K. Rheum. Dis. Clin. North Am. (2004) [Pubmed]
  56. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. Wolfe, F., Michaud, K. J. Rheumatol. (2004) [Pubmed]
  57. The Short Arthritis Assessment Scale: a brief assessment questionnaire for rapid evaluation of arthritis severity in research and clinical practice. Wolfe, F., Michaud, K., Kahler, K., Omar, M. J. Rheumatol. (2004) [Pubmed]
  58. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. Wolfe, F., Freundlich, B., Straus, W.L. J. Rheumatol. (2003) [Pubmed]
  59. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. Wolfe, F. J. Rheumatol. (2003) [Pubmed]
  60. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Wolfe, F., Pincus, T., Thompson, A.K., Doyle, J. Arthritis Rheum. (2003) [Pubmed]
  61. Predicting mortality in patients with rheumatoid arthritis. Wolfe, F., Michaud, K., Gefeller, O., Choi, H.K. Arthritis Rheum. (2003) [Pubmed]
  62. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. Wolfe, F., Michaud, K., Stephenson, B., Doyle, J. J. Rheumatol. (2003) [Pubmed]
  63. Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs. Wolfe, F., Michaud, K., Zhao, S.Z. J. Clin. Rheumatol (2003) [Pubmed]
  64. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. Wolfe, F., Anderson, J., Burke, T.A., Arguelles, L.M., Pettitt, D. J. Rheumatol. (2002) [Pubmed]
  65. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. Wolfe, F., Flowers, N., Burke, T.A., Arguelles, L.M., Pettitt, D. J. Rheumatol. (2002) [Pubmed]
  66. The determination and measurement of functional disability in rheumatoid arthritis. Wolfe, F. Arthritis Res. (2002) [Pubmed]
  67. Radiographic methods in knee osteoarthritis: a further comparison of semiflexed (MTP), schuss-tunnel, and weight-bearing anteroposterior views for joint space narrowing and osteophytes. Wolfe, F., Lane, N.E., Buckland-Wright, C. J. Rheumatol. (2002) [Pubmed]
  68. Radiography of rheumatoid arthritis in the time of increasing drug effectiveness. Wolfe, F., Strand, V. Curr. Rheumatol. Rep (2001) [Pubmed]
  69. Evaluating severity and status in rheumatoid arthritis. Wolfe, F., O'Dell, J.R., Kavanaugh, A., Wilske, K., Pincus, T. J. Rheumatol. (2001) [Pubmed]
  70. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. Wolfe, F., Rehman, Q., Lane, N.E., Kremer, J. J. Rheumatol. (2001) [Pubmed]
  71. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. Wolfe, F., Pincus, T., O'Dell, J. J. Rheumatol. (2001) [Pubmed]
  72. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. Wolfe, F., Pincus, T. J. Rheumatol. (2001) [Pubmed]
  73. Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement. Wolfe, F., Choi, H.K. Ann. Rheum. Dis. (2001) [Pubmed]
  74. Measuring the epidemiology of distress: the rheumatology distress index. Wolfe, F., Skevington, S.M. J. Rheumatol. (2000) [Pubmed]
  75. Assessing radiographic status of rheumatoid arthritis: introduction of a short erosion scale. Wolfe, F., van der Heijde, D.M., Larsen, A. J. Rheumatol. (2000) [Pubmed]
 
WikiGenes - Universities